📇 Rhumatologue · LA ROCHELLE CEDEX 1 · (17) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
11 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
120.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL SAINT-LOUIS - LA ROCHELLE
R DU DR SCHWEITZER, 17019 LA ROCHELLE CEDEX 1
CABINET PRIVE DU DR PHILIPPE CELERIER
SERVICE DE DERMATOLOGIE CENTRE HOSPITALIER LA ROCHELLE RUE DU DR SCHWEITZER, 17019 LA ROCHELLE CEDEX 1
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Archives of dermatology · 2008
Rheumatology (Oxford, England) · 2021
Abstract Objectives The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechallenge. Methods We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analysed in both groups. The modalities and outcomes of ICI rechallenge were reviewed. Results Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n = 14/16) and all had a complete response within ≤3 weeks. The efficacy of oral steroids for non-severe typical irM (n = 10) was the same with low-dose (≤0.5 mg/kg/day) or high-dose (1 mg/kg/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n = 4) had a less favourable evolution, including one irM-related death, and required heavy immunosuppression. ICIs were safely reintroduced in nine patients presenting a moderate (n = 6) or a severe (n = 3) irM. Conclusion Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favour of a safe reintroduction of ICI following symptom resolution and creatin kinase (CK) normalization in moderate and severe forms of irM.
Acta dermato-venereologica · 2024
Acne in adult females is triggered mainly by hormones. Doxycycline is a reference treatment in acne. Spironolactone targets the androgen receptor of sebaceous glands and is prescribed off-label for female adult acne. This multicentre, controlled, randomized, double-blind prospective and parallel study assessed the efficacy of spironolactone compared with doxycycline in adult female acne. A total of 133 women with moderate acne were randomized to receive treatment with: (i) doxycycline and benzoyl peroxide for 3 months followed by a 3-month treatment with its placebo and benzoyl peroxide, or (ii) spironolactone and benzoyl peroxide for 6 months. Successfully treated patients continued with benzoyl peroxide or spironolactone alone for a further 6 months. Primary endpoints were treatment success at month 4 and month 6 with the AFAST score. At all visits, the ECLA score, lesion counts, local and systemic safety and quality of life were assessed. Spironolactone performed better at month 4 and showed a statistically significant better treatment success after 6 months than doxycycline (p = 0.007). Spironolactone was 1.37-times and 2.87-times more successful compared with doxycycline at respective time-points. AFAST and ECLA scores, as well as lesion counts always improved more with spironolactone. Patients’ quality of life was better with spironolactone at month 4 and month 6. Spironolactone was very well tolerated. This is the first study to show that, in female adults with moderate acne, treatment with spironolactone is significantly more successful than doxycycline and very well tolerated.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of dermatology : EJD · 2022 · Journal Article
L'Orphelin JM, Le Naour S, Dalle S, Varey E, et al.
European journal of dermatology : EJD · 2019 · Case Reports
Barbarin C, Hosteing S, Nosbaum A, Allouchery M, et al.
International wound journal · 2015 · Journal Article
Leloup P, Toussaint P, Lembelembe JP, Célérier P, et al.
Annales de dermatologie et de venereologie · 2008 · Case Reports
Wastiaux H, Maillard H, Bara C, Catala S, et al.
Archives of dermatology · 2008 · Comparative Study
Quereux G, Marques S, Nguyen JM, Bedane C, et al.
Acta dermato-venereologica · 2024 · Randomized Controlled Trial
Dréno B, Nguyen JM, Hainaut E, Machet L, et al.
Cancers · 2022 · Journal Article
Marcé D, Le Vilain-Abraham F, Bridou M, Quéreux G, et al.
Journal of wound care · 2019 · Journal Article
Meaume S, Thomas P, Truchetet F, Celerier P, et al.
Rheumatology international · 2012 · Case Reports
Guerin M, Haettich B, Bara C, Artru L, et al.
Rheumatology (Oxford, England) · 2021 · Journal Article
Weill A, Delyon J, Descamps V, Deschamps L, et al.
Annales de dermatologie et de venereologie · 2012 · Case Reports
Gelot P, Maillard H, De Ybarlucea LR, Bara C, et al.